# A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients

> **NCT00189267** · PHASE2 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 45 (—)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Imiquimod 5 % Cream

## Key facts

- **NCT ID:** NCT00189267
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 45 (—)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189267, "A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00189267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*